Polyrizon (NASDAQ:PLRZ) & Briacell Therap (NASDAQ:BCTX) Head-To-Head Review

Polyrizon (NASDAQ:PLRZ) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability.

Institutional & Insider Ownership

15.4% of Briacell Therap shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Polyrizon and Briacell Therap, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1	0	0	0	1.00
Briacell Therap	1	0	1	0	2.00

Briacell Therap has a consensus price target of $320.00, suggesting a potential upside of 6,948.46%. Given Briacell Therap’s stronger consensus rating and higher possible upside, analysts clearly believe Briacell Therap is more favorable than Polyrizon.

Valuation and Earnings

This table compares Polyrizon and Briacell Therap”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34 million	N/A	N/A
Briacell Therap	N/A	N/A	-$26.31 million	($23.33)	-0.19

Profitability

This table compares Polyrizon and Briacell Therap’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Briacell Therap	N/A	-173.08%	-139.64%

Volatility & Risk

Polyrizon has a beta of -4.6, indicating that its stock price is 560% less volatile than the S&P 500. Comparatively, Briacell Therap has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Summary

Briacell Therap beats Polyrizon on 6 of the 9 factors compared between the two stocks.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.